Skip to content

CND Life Sciences

4 viewers · 30d

Total raised

$15.0M

+$6.3M this year

3 filings since 2025 · latest Debt filed

Cumulative raised
LAST ROUND
Debt · $6.3M
ROUNDS
3
INVESTORS
27
FOUNDED
N/A
HQ
N/A
SECTOR
Healthcare
EMPLOYEES
N/A
30D VIEWERS
4

AI overview

Updated

CND Life Sciences, Inc. is a pioneering medical technology company focused on developing diagnostic solutions for neurodegenerative diseases, particularly those related to abnormal protein accumulation in the nervous system. Their innovative approach centers around minimally invasive skin-based diagnostics aimed at improving the accuracy of diagnosing conditions like Parkinson’s disease and related disorders.

What sets it apart

The company stands out for its Syn-One Test®, the first commercially available test that detects misfolded alpha-synuclein proteins using simple skin biopsies.

Funding history

3 rounds
DebtJun 9, 2026 · $25K min
Form D
+$4.3M$15.0M total
DebtJun 9, 2026 · $25K min
Form D/A
+$6.3M$15.0M total
EquityFeb 28, 2025 · $25K min
Form D/A
+$8.6M$8.6M total

Products

1 tracked

Syn-One Test®

Diagnostic Testing

The Syn-One Test® is a groundbreaking, minimally invasive diagnostic tool that detects and quantifies the presence of misfolded, phosphorylated alpha-synuclein in skin nerve fibers. This test is processed in a CLIA-certified and CAP-accredited laboratory through a straightforward procedure that requires three small skin biopsy samples.

  • World's first commercially available skin-based diagnostic test
  • High sensitivity and specificity rates exceeding 95%
  • Utilizes proprietary immunofluorescence techniques and NerValence™ AI pathology

Links

WebsiteLinkedInSEC EDGAR filings